Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients.
Cellular immunotherapy has appeared to be a promising modality for the treatment of malignant tumor. The objective of this study was to evaluate the efficacy of cellular immunotherapy combined with minimally invasive therapy.We searched PubMed, Web of Science and The Cochrane Library through March 2...
Main Authors: | Min Ding, Ying Wang, Jiachang Chi, Tao Wang, Xiaoyin Tang, Dan Cui, Qijun Qian, Bo Zhai |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5179243?pdf=render |
Similar Items
-
Efficacy assessment of DC-CIK immunotherapy combined with TACE and RFA treatment of primary hepatocellular carcinoma
by: Xin-Hua Zuo, et al.
Published: (2016-02-01) -
The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
by: Jung Hee Kim, et al.
Published: (2017-03-01) -
Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
by: Li Chen, et al.
Published: (2021-03-01) -
Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
by: Wang Yao, et al.
Published: (2020-12-01) -
Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma
by: Dong, C., et al.
Published: (2022)